BACKGROUND: Patients with relapsing-remitting multiple sclerosis (RRMS) who experience relapses on a first-line therapy (interferon, glatiramer acetate, dimethyl fumarate, or teriflunomide; collectively, "BRACETD") often switch to another therapy, including natalizumab or fingolimod. Here we compare the effectiveness of switching from a first-line therapy to natalizumab or fingolimod after ≥1 relapse. METHODS: Data collected prospectively in the MSBase Registry, a global, longitudinal, observational registry, were extracted on February 6, 2018. Included patients were adults with RRMS with ≥1 relapse on BRACETD therapy in the year before switching to natalizumab or fingolimod. Included patients received natalizumab or fingolimod for ≥3 months after the switch. RESULTS: Following 1:1 propensity score matching, 1000 natalizumab patients were matched to 1000 fingolimod patients. Mean (standard deviation) follow-up time was 3.02 (2.06) years after switching to natalizumab and 2.58 (1.64) years after switching to fingolimod. Natalizumab recipients had significantly lower annualized relapse rate (relative risk=0.66; 95% confidence interval [CI], 0.59-0.74), lower risk of first relapse (hazard ratio [HR]=0.69; 95% CI, 0.60-0.80), and higher confirmed disability improvement (HR=1.27; 95% CI, 1.03-1.57) than fingolimod recipients. No difference in confirmed disability worsening was observed. CONCLUSIONS: Patients with RRMS switching from BRACETD demonstrated better outcomes with natalizumab than with fingolimod.

Central Clinical School and Department of Neurology Monash University and Department of Neurology Alfred Hospital Melbourne VIC Australia

Central Clinical School Monash University Melbourne VIC Australia and Department of Clinical Neuroscience Karolinska Institute Stockholm Sweden

CISSS de Chaudière Appalaches Lévis QC Canada

CORe Department of Medicine University of Melbourne and Department of Neurology Royal Melbourne Hospital Melbourne VIC Australia

Department of Medical and Surgical Sciences and Advanced Technologies GF Ingrassia AOU Policlinico Vittorio Emanuele and Policlinico G Rodolico Catania Italy

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Czech Republic

Department of Neurology Faculty of Medicine University of Debrecen Debrecen Hungary

Department of Neurology Monash University Melbourne VIC Australia

Department of Neuroscience Imaging and Clinical Sciences University G d'Annunzio Chieti Italy

Division of Neurology Department of Medicine Amiri Hospital Sharq Kuwait

Dokuz Eylul University Konak Izmir Turkey

Hôpital Notre Dame Montreal QC Canada and CHUM and Université de Montréal Montreal QC Canada

KTU Medical Faculty Farabi Hospital Trabzon Turkey

Medical Faculty 19 Mayis University Samsun Turkey

Neuro Rive Sud QC Canada

Neurosciences Unit Department of Medicine and Surgery University of Parma Parma Italy

School of Medicine and Public Health University Newcastle and Department of Neurology John Hunter Hospital Hunter New England Health Newcastle NSW Australia

000      

00000naa a2200000 a 4500

001      

bmc23004284

003      

CZ-PrNML

005      

20230425141248.0

007      

ta

008      

230418s2023 ne f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.msard.2022.104477 $2 doi

035    __

$a (PubMed)36746088

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Spelman, Tim $u Central Clinical School, Monash University, Melbourne, VIC, Australia, and Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden. Electronic address: tim@burnet.edu.au

245    10

$a Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity / $c T. Spelman, D. Horakova, S. Ozakbas, R. Alroughani, M. Onofrj, T. Kalincik, A. Prat, M. Terzi, P. Grammond, F. Patti, T. Csepany, C. Boz, J. Lechner-Scott, F. Granella, F. Grand'Maison, A. van der Walt, C. Zhu, H. Butzkueven, MSBase Study Group

520    9_

$a BACKGROUND: Patients with relapsing-remitting multiple sclerosis (RRMS) who experience relapses on a first-line therapy (interferon, glatiramer acetate, dimethyl fumarate, or teriflunomide; collectively, "BRACETD") often switch to another therapy, including natalizumab or fingolimod. Here we compare the effectiveness of switching from a first-line therapy to natalizumab or fingolimod after ≥1 relapse. METHODS: Data collected prospectively in the MSBase Registry, a global, longitudinal, observational registry, were extracted on February 6, 2018. Included patients were adults with RRMS with ≥1 relapse on BRACETD therapy in the year before switching to natalizumab or fingolimod. Included patients received natalizumab or fingolimod for ≥3 months after the switch. RESULTS: Following 1:1 propensity score matching, 1000 natalizumab patients were matched to 1000 fingolimod patients. Mean (standard deviation) follow-up time was 3.02 (2.06) years after switching to natalizumab and 2.58 (1.64) years after switching to fingolimod. Natalizumab recipients had significantly lower annualized relapse rate (relative risk=0.66; 95% confidence interval [CI], 0.59-0.74), lower risk of first relapse (hazard ratio [HR]=0.69; 95% CI, 0.60-0.80), and higher confirmed disability improvement (HR=1.27; 95% CI, 1.03-1.57) than fingolimod recipients. No difference in confirmed disability worsening was observed. CONCLUSIONS: Patients with RRMS switching from BRACETD demonstrated better outcomes with natalizumab than with fingolimod.

650    _2

$a dospělí $7 D000328

650    _2

$a lidé $7 D006801

650    _2

$a fingolimod hydrochlorid $7 D000068876

650    _2

$a imunologické faktory $7 D007155

650    _2

$a imunosupresiva $7 D007166

650    12

$a roztroušená skleróza $7 D009103

650    12

$a relabující-remitující roztroušená skleróza $7 D020529

650    _2

$a natalizumab $7 D000069442

650    _2

$a recidiva $7 D012008

650    _2

$a výsledek terapie $7 D016896

650    _2

$a srovnávací výzkum účinnosti $7 D057186

655    _2

$a časopisecké články $7 D016428

700    1_

$a Horakova, Dana $u Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic

700    1_

$a Ozakbas, Serkan $u Dokuz Eylul University, Konak, Izmir, Turkey

700    1_

$a Alroughani, Raed $u Division of Neurology, Department of Medicine, Amiri Hospital, Sharq, Kuwait

700    1_

$a Onofrj, Marco $u Department of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio, Chieti, Italy

700    1_

$a Kalincik, Tomas $u CORe, Department of Medicine, University of Melbourne, and Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia

700    1_

$a Prat, Alexandre $u Hôpital Notre Dame, Montreal, QC, Canada, and CHUM and Université de Montréal, Montreal, QC, Canada

700    1_

$a Terzi, Murat $u Medical Faculty, 19 Mayis University, Samsun, Turkey

700    1_

$a Grammond, Pierre $u CISSS de Chaudière-Appalaches, Lévis, QC, Canada

700    1_

$a Patti, Francesco $u Department of Medical and Surgical Sciences and Advanced Technologies, GF Ingrassia, AOU Policlinico Vittorio Emanuele, and Policlinico G. Rodolico, Catania, Italy

700    1_

$a Csepany, Tunde $u Department of Neurology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary

700    1_

$a Boz, Cavit $u KTU Medical Faculty Farabi Hospital, Trabzon, Turkey

700    1_

$a Lechner-Scott, Jeannette $u School of Medicine and Public Health, University Newcastle, and Department of Neurology, John Hunter Hospital, Hunter New England Health, Newcastle, NSW, Australia

700    1_

$a Granella, Franco $u Neurosciences Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy

700    1_

$a Grand'Maison, Francois $u Neuro Rive-Sud, QC, Canada

700    1_

$a van der Walt, Anneke $u Department of Neurology, Monash University, Melbourne, VIC, Australia

700    1_

$a Zhu, Chao $u Department of Neurology, Monash University, Melbourne, VIC, Australia

700    1_

$a Butzkueven, Helmut $u Central Clinical School and Department of Neurology, Monash University, and Department of Neurology, Alfred Hospital, Melbourne, VIC, Australia

710    2_

$a MSBase Study Group

773    0_

$w MED00188780 $t Multiple sclerosis and related disorders $x 2211-0356 $g Roč. 70, č. - (2023), s. 104477

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36746088 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y p $z 0

990    __

$a 20230418 $b ABA008

991    __

$a 20230425141244 $b ABA008

999    __

$a ok $b bmc $g 1924762 $s 1190493

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 70 $c - $d 104477 $e 20221223 $i 2211-0356 $m Multiple sclerosis and related disorders $n Mult Scler Relat Disord $x MED00188780

LZP    __

$a Pubmed-20230418